IP Library Granted Patent US 9,616,041
Granted Patent B2
US 9,616,041 · App. 13/694,592 · Granted Apr 11, 2017

Methods and compositions for the treatment of diverticulosis

Inventor: Yutaka Niihara (Rolling Hills Estates, CA)
Assignee: Emmaus Medical, Inc.
A61K31/198A61K31/717A61K31/721A61K36/68
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,616,041
App. No.
13/694,592
Granted
Apr 11, 2017
Kind
B2
Abstract

The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.

Claims (4)

1. A method of treating diverticulosis, wherein the method consists of ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine or an L-glutamine salt per day as a solution by a person who has diverticulosis, wherein L-glutamine or an L-glutamine salt is the only active ingredient in the solution, and wherein the person who has diverticulosis has a number of diverticula, and wherein the number of diverticula in the person with diverticulosis is reduced by at least fifty percent after ingesting the solution for a period of at least three months.

2. The method according to claim 1 , wherein the compound ingested is L-glutamine, and wherein L-glutamine is the only active ingredient in the solution.

3. The method according to claim 1 , wherein the L-glutamine is ingested for a period of at least six months.

4. The method according to claim 3 , wherein the number of diverticula in the person with diverticulosis is reduced by at least seventy-five percent.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 4, 2018
From: GPB DEBT HOLDINGS II, LLC
To: EMMAUS LIFE SCIENCES, INC.; EMMAUS MEDICAL, INC.
Reel/Frame 045720/0155 →
SECURITY INTEREST Recorded Jan 3, 2018
From: EMMAUS LIFE SCIENCES, INC.; EMMAUS MEDICAL, INC.
To: GPB DEBT HOLDINGS II, LLC.
Reel/Frame 044527/0094 →
RELEASE OF SECURITY INTEREST Recorded Oct 4, 2016
From: AGILITY CAPITAL II, LLC
To: EMMAUS LIFE SCIENCES, INC.; EMMAUS MEDICAL, INC.
Reel/Frame 039936/0239 →
SECURITY INTEREST Recorded Apr 21, 2016
From: EMMAUS LIFE SCIENCES, INC.; EMMAUS MEDICAL, INC.
To: AGILITY CAPITAL II, LLC
Reel/Frame 038337/0082 →
Continuity (2)
Provisional Application 61630831 · Dec 19, 2011
Related Publication 20130178531A1 · Jul 11, 2013